Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Mikhail Samsonov"'
Autor:
Veronika Voronova, Anastasia Vislobokova, Kerim Mutig, Mikhail Samsonov, Kirill Peskov, Marina Sekacheva, Maria Materenchuk, Natalya Bunyatyan, Svetlana Lebedeva
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Immuno-oncology is an emerging field in the treatment of oncological diseases, that is based on recruitment of the host immune system to attack the tumor. Radiation exposure may help to unlock the potential of the immune activating agents by enhancin
Externí odkaz:
https://doaj.org/article/5ed6a06f62424c2ca41daf7655f2216c
Autor:
Andrey Kulikov, Elena Shipaeva, Anastasia Dmitrieva, Vera Batrak, Georgy Shipunov, Colin Guy, Jill Smith, Ran Zhang, Michael Zhang, Jeff Duan, Anton Chestukhin, Sergei Barbashov, Mikhail Samsonov, Yan Lavrovsky
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
RPH-120 is a novel fully human anti-PD-L1 IgG1 monoclonal antibody with specifically designed Asn300Ala mutation in Fc fragment. Surface plasmon resonance assay showed that affinity of the RPH-120 to the dimeric form of human PD-L1-Fc fusion protein
Externí odkaz:
https://doaj.org/article/5dbb2234d8f24276a1a0965cf6215e2e
Autor:
Mikhail Samsonov
Publikováno v:
Ибероамериканские тетради, Vol 0, Iss 4, Pp 19-22 (2018)
The paper analyzes the activity of the Russian company «Power Machines PJSC» in Argentina and Brazil as an example of the Russian – Latin American energy cooperation in the 21st century. In this work, the chronology of the Russian company’s act
Externí odkaz:
https://doaj.org/article/b313497c20f44065b1bd3cc978a5ffb1
Autor:
Nikolay Kuzmich, Elena Andresyuk, Yuri Porozov, Vadim Tarasov, Mikhail Samsonov, Nina Preferanskaya, Valery Veselov, Renad Alyautdin
Publikováno v:
Molecules, Vol 27, Iss 2, p 434 (2022)
PCSK9 has now become an important target to create new classes of lipid-lowering drugs. The prevention of its interaction with LDL receptors allows an increase in the number of these receptors on the surface of the cell membrane of hepatocytes, which
Externí odkaz:
https://doaj.org/article/daf3fbdf2ef54b5581001ff7d3346a08
Publikováno v:
Clinical and Translational Medicine, Vol 7, Iss 1, Pp 1-14 (2018)
Abstract Yes-associated protein (YAP) and its paralog WW domain containing transcription regulator 1 (TAZ) are important regulators of multiple cellular functions such as proliferation, differentiation, and survival. On the tissue level, YAP/TAZ are
Externí odkaz:
https://doaj.org/article/5d6e7ac9680b4721bb18b6f465e04c4e
Autor:
Eugen Feist, Saeed Fatenejad, Sergey Grishin, Elena Korneva, Michael E Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen, Roy M Fleischmann
Publikováno v:
Modern Rheumatology Journal. 17:23-26
ObjectivesTo assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs).MethodsI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9da1b928747915d791bf834ce64c4d62
https://doi.org/10.14412/1996-7012-2023-2-23-36
https://doi.org/10.14412/1996-7012-2023-2-23-36
Autor:
Michael E. Luggen, Evgeniy L Nasonov, Sergey Grishin, Eugen Feist, Elena Korneva, Saeed Fatenejad, Mikhail Samsonov
Publikováno v:
Rheumatology. 60
Background/Aims Olokizumab (OKZ) is a new humanised monoclonal antibody targeting IL-6. Here we present the results of the phase III study of OKZ in anti-TNF-IR patients. Methods Patients with moderately to severely active RA who had previously faile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::077e50bf22933e6c1b2ffb282ddad694
https://doi.org/10.1093/rheumatology/keab247.132
https://doi.org/10.1093/rheumatology/keab247.132
Autor:
Elena Korneva, Sergey Grishin, Eugen Feist, Evgeniy L Nasonov, Saeed Fatenejad, Mikhail Samsonov, Anna Rowińska-Osuch, Saima Chohan
Publikováno v:
Rheumatology. 60
Background/Aims Olokizumab (OKZ) is a new humanised monoclonal antibody targeting IL-6 directly. Here we present the results of a global randomised clinical trial (RCT) in patients (pts) with RA. Methods This double-blind, placebo (PBO) and active co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d5904116098f157c3e26041bb26359a
https://doi.org/10.1093/rheumatology/keab247.126
https://doi.org/10.1093/rheumatology/keab247.126
Autor:
E. Zonova, Elena Korneva, Mikhail Samsonov, Mariana Ivanova, Saeed Fatenejad, D. G. Krechikova, Aleksey L Maslyanskiy, Rumen Stoilov, Evgeniy Nasonov, Eugen Feist, Mark C. Genovese
Publikováno v:
Annals of the rheumatic diseases. 81(4)
ObjectiveTo evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX).MethodsIn this 24-week multicentre, placebo-controlled, double-blind study, patients were randomis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0befe0904e08d59e3feebb139ec213eb
https://pubmed.ncbi.nlm.nih.gov/34344706
https://pubmed.ncbi.nlm.nih.gov/34344706
Publikováno v:
Experimental Gerontology. 113:29-35
Progesterone hormone (P4) is a promising agent against strokes because post-ischemic administration of P4 exerts neuroprotective effects in several young and aged animal models of stroke. However, in contrast to a majority of the studies using male a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77be352ba57c538c7502527dd0587ddf
https://doi.org/10.1016/j.exger.2018.09.012
https://doi.org/10.1016/j.exger.2018.09.012